The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...

Evolus faces sector instability but shows strong growth potential. Learn why EOLS stock remains a “Buy” despite challenges, ...

AbbVie’s ABBV stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

Cosmetic Surgery Industry The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and collaboration< ...